Clinical trials: Apixaban
Pulmonary Embolism (PE), Pulmonary Thromboembolism
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
A study based on a chart review of participants that presented with a sudden blood clot in the lung
- Trial name
- NCT03595891
- Testing
- Non-Interventional
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- Bristol-Myers Squibb
Antithrombic Drug
Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects
To compare the bioavailability and characterize the pharmacokinetic profile of the sponsor's test product relative to that of reference product after single oral dose administration in normal, healthy, adult, human subjects under…
- Trial name
- NCT06043297
- Testing
- Apixaban 5MG, Eliquis 5 mg
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Non-valvular Atrial Fibrillation (AF)
Vortosiran in Atrial Fibrillation
This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF.
- Trial name
- NCT07870889
- Testing
- Vortosiran, Apixaban
- Where
- 15 sites in Denmark, Norway and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Anticoagulation
Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden
This will be a retrospective cohort study using national register linkage data (including prescription, inpatient, mortality, and socioeconomic data). The study period will be from May 29, 2013 to June 30, 2015.
- Trial name
- NCT02492828
- Volunteers
- 41,000 people
- Sponsor
- Bristol-Myers Squibb
Antiphospholipid Syndrome, Thrombosis
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a…
- Trial name
- ASTRO-APS (NCT02295475)
- Testing
- Apixaban, Warfarin
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Scott C. Woller, MD
Spinal Cord Injuries, Venous Thromboembolism
Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
Thromboprophylaxis options are limited for patients with acute spinal cord injury (SCI) and there are no studies on direct oral anticoagulants (DOACs) for thromboprophylaxis in this population.
- Trial name
- NCT03200613
- Testing
- Apixaban, Low molecular weight heparin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Thrombosis, Deep Vein, Pulmonary Embolism
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
Number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in Mexico.
- Trial name
- NCT03812835
- Sponsor
- Pfizer
Anticoagulants
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Single-institution uncontrolled open-label trial.
- Trial name
- NCT05319340
- Testing
- prescribing anticoagulant therapy
- Volunteers
- 1,000 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Glioblastoma, Astrocytoma
Venous Thromboembolism Prevention in Outpatients With Glioma
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
- Conditions
- Glioblastoma, Astrocytoma, Venous Thromboembolism
- Trial name
- VTE-POG (NCT05683808)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Vermont Medical Center
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Stroke, Atrial Fibrillation
The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation
This study aims to determine whether there is a difference in brain lesion occurrence and safety when brain MRI is followed up between edoxaban and apixaban in stroke patients with nonvalvular atrial fibrillation through…
- Trial name
- APIXABAN (NCT06864052)
- Testing
- Administration of Apixaban, Administration of Edoxaban
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Ewha Womans University Seoul Hospital
Ischaemic Stroke
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice.
- Trial name
- ELAN (NCT03148457)
- Testing
- Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®), Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
- Where
- 98 sites in Austria, Belgium and 13 more
- Volunteers
- 2,013 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban…
- Trial name
- NCT00423319
- Testing
- Enoxaparin, Apixaban
- Where
- 143 sites in United States, Argentina and 19 more
- Volunteers
- 5,407 people
- Sponsor
- Bristol-Myers Squibb
Deep Vein Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban…
- Trial name
- NCT00371683
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 3,608 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of…
- Trial name
- DARING-AF (NCT02666157)
- Testing
- Dabigatran etexilate, Rivaroxaban, Apixaban
- Where
- 5 sites in Taiwan
- Volunteers
- 3,672 people
- Sponsor
- National Cheng-Kung University Hospital
Thrombosis
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet
- Trial name
- NCT00914641
- Testing
- Apixaban IR, Apixaban MR1, Apixaban MR2
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atrial Fibrillation, Atrial Flutter
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)
People receiving dialysis are more likely to develop atrial fibrillation (AF), an irregular heartbeat that increases the risk of stroke.
- Conditions
- Atrial Fibrillation, Atrial Flutter, End Stage Kidney Disease (ESRD), Dialysis Patients
- Trial name
- SAFE-D2 (NCT07779746)
- Testing
- Eliquis, No oral anticoagulation
- Volunteers
- 848 people
- Sponsor
- Unity Health Toronto
NonValvular Atrial Fibrillation
Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
The primary objectives of this study are: To estimate the incidence rate of unexpected adverse events To characterize the bleeding events and assess risk factors of bleeding To identify ancillary baseline variables that may also…
- Trial name
- NCT02007655
- Testing
- Eliquis
- Where
- Japan
- Volunteers
- 6,372 people
- Sponsor
- Bristol-Myers Squibb
Acute Deep Vein Thrombosis, Acute Pulmonary Embolism
Registry of Patients Prescribed Anticoagulation
The Gonda Vascular Center- Thrombophilia Clinic at Mayo Clinic in Rochester, Minnesota utilizes a standardized, guideline-directed, yet patient-oriented approach for treating patients diagnosed with venous thromboembolism…
- Trial name
- STAGPOR (NCT03504007)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Mayo Clinic
Atrial Fibrillation (AF)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-ATLAS (NCT07175428)
- Testing
- REGN7508, REGN9933, Apixaban
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Regeneron Pharmaceuticals